Literature DB >> 24282792

Gender difference in Cisplatin-induced nephrotoxicity in a rat model: greater intensity of damage in male than female.

Mehdi Nematbakhsh1, Shadi Ebrahimian, Mona Tooyserkani, Fatemeh Eshraghi-Jazi, Ardeshir Talebi, Farzaneh Ashrafi.   

Abstract

BACKGROUND: Nephrotoxicity and hepatotoxicity are side effects of Cisplatin (CP) therapy.
OBJECTIVES: We investigated the role of gender in CP-induced nephrotoxicity and hepatotoxicity.
MATERIALS AND METHODS: Low dose of CP (1 mg/kg/day; ip) was administered daily to male and female Wistar rats for 15 consecutive days. Serum creatinine (Cr), blood urea nitrogen (BUN), malondialdehyde (MDA), nitric oxide (NO) metabolite, and magnesium (Mg) levels were determined.
RESULTS: The percentage of weight loss and the serum levels of MDA and nitrite in male and female animals were not statistically different. However, the serum levels of BUN, Cr, Mg, and kidney MDA levels, and kidney weight and damage score were significantly greater in males than in females (P < 0.05).
CONCLUSIONS: CP-induced nephrotoxicity is gender related for which the mechanisms should be determined.

Entities:  

Keywords:  Cisplatin; Gender; Rats; Renal Insufficiency

Year:  2013        PMID: 24282792      PMCID: PMC3830908          DOI: 10.5812/numonthly.10128

Source DB:  PubMed          Journal:  Nephrourol Mon        ISSN: 2251-7006


1. Background

Cisplatin (CP) is one of the most common drugs used in clinics to treat different types of cancer such as sarcomas, some carcinomas, germ cell tumors, and lymphomas. However, CP therapy is accompanied by moderate to severe nephrotoxicity. In general, the drug-induced nephrotoxicity may be gender related. The serum levels of creatinine and urea in a model of gentamycin-induced nephrotoxicity were higher in males than females (1, 2). It has been documented that males suffer more from renal injury by Amphotericin B (3) and Tobramycin (4) than females. Moreover, the probability of nephrotoxicity induced by Phenobarbital is higher in male rats than females (5). In addition, male animals are less resistant to ischemic acute renal failure than females (6). It has been reported that the neuropathy induced by CP is gender related (7), and CP interacts with female sex hormones and therefore, estradiol administration prevents the protective role of some antioxidants against CP-induced nephrotoxicity (8). Furthermore, L-arginine and losartan have more protective effects against CP-induced nephrotoxicity in male than in female (9, 10). A preliminary report also indicated that CP-induced nephrotoxicity may be sex related (11). Further studies were suggested to clearly differentiate between CP side effects and the role of gender (7, 11).

2. Objectives

The present study was designed to find gender differences of nephrotoxicity induced by daily administration of low doses of CP to rats for two weeks.

3. Materials and Methods

Fifteen Wistar rats (male; n = 7, weight 200 ± 6 g; female; n = 8, weight 167 ± 4 g) were randomly divided into two experiment groups. The animals were housed under standard conditions with 12 h light/12 h dark cycles and were given ad libitum access to food and water. The experiments were confirmed to be in accordance with the guidelines of animal ethics committee of Isfahan university of medical sciences.

3.1. Experimental Protocols

The animals received CP daily (1 mg/kg/day; ip) for two weeks. CP was purchased from EBEWE PharmaGes.m.b.H (Austria). The body weight of animals was recorded on a daily basis. At the end of the experiment, blood samples were obtained and the rats were then sacrificed. The kidneys were immediately removed and weighed. The left kidney was subjected to histopathological investigations, and the right kidney was homogenized and centrifuged for determination of the supernatant Malondialdehyde (MDA) levels. A sample of liver was also obtained to investigate hepatotoxicity damage induced by CP.

3.2. Measurements

Serum creatinine (Cr), blood urea nitrogen (BUN), and magnesium (Mg) levels were determined using quantitative kits (Pars Azmoon, Iran). The serum level of nitrite (stable NO metabolite) was measured using a colorimetric assay kit (Promega Corporation, USA). MDA levels of serum and the supernatant from homogenized tissue were quantified according to the manual methodology (12). Briefly, 500 µL of the sample was mixed with 1000 µL 10% trichloroacetic acid (TCA). The mixture was vigorously shaken and centrifuged at 2000 g for 10 minutes; 500 µL of the supernatant was added to 500 µL 0.67% thiobarbituric acid (TBA). The solution was then incubated in a hot water bath at the temperature of 100 ºC for 10 minutes. After cooling, the absorbance was measured at 532 nm. The concentration of MDA was reported as µmol/L for the serum and as µmol/100 g of tissue for kidney.

3.3. Histopathological Procedures

The kidney and liver tissues were fixed in 10% formalin solution, embedded in paraffin for histopathological staining. Hematoxylin and eosin staining was applied to examine the tubular injury. For kidney damage, presence of acute tubular damage such as tubular dilation and simplification, tubular cell swelling and necrosis, tubular casts, and intraluminal cell debris with inflammatory cell infiltration were considered. The intensity of tubular lesions as mentioned above, were scored from 1 to 4, while score zero was assigned to normal tissue without damage. For the liver tissue, any damage including the presence of lymphocytes was determined.

3.4. Statistical Analysis

Data are presented as mean ± SEM. To compare the weight change between the groups, repeated measures analysis was applied. The groups were compared with unpaired Student’s t-test for kidney weight, serum levels of BUN, Cr, MDA, Mg, and nitrite; and kidney tissue level of MDA. Mann-Whitney test was employed to compare the pathological damage score among the groups. P-values < 0.05 were considered statistically significant.

4. Results

The percentage of weight loss in male animals was 13.8 ± 2.1% while female animals lost about 11.8 ± 2.6% of their weight, and the difference between male and female rats was not statistically significant. The data for the serum levels of BUN, Cr, MDA, Mg, and NO, kidney weight and renal MDA level, and pathology damage scores are demonstrated in Figure 1. Except for the serum levels of MDA and NO, the other parameters were significantly different between male and female (P < 0.05) (Figure 1). The pathological data indicated a few lymphocytes in most samples, and no other abnormalities were observed for liver tissue. Therefore, we presume that no damage was induced by CP in the protocol of this study. The images of the kidney and liver tissues of both genders are shown in Figure 2. More damage was observed in the male kidney tissues.
Figure 1.

Serum Levels of BUN, Cr, Mg, MDA, and Nitrite, Kidney MDA, Kidney weight/100 g body Weight, and Kidney Damage Scores in Male and Female Animals Treated With CP

Figure 2.

The Images of Kidney and Liver Tissues (magnification x 100).

More damage of kidney tissue was observed in male than in female, but no damage was detected in liver tissues of both sexes. KM: kidney tissue of male, KF: kidney tissue of female, LM: liver tissue of male, and LF: liver tissue of female.

The Images of Kidney and Liver Tissues (magnification x 100).

More damage of kidney tissue was observed in male than in female, but no damage was detected in liver tissues of both sexes. KM: kidney tissue of male, KF: kidney tissue of female, LM: liver tissue of male, and LF: liver tissue of female.

5. Discussion

The main purpose of this study was to detect sex-related nephrotoxicity induced by CP. We found that the biochemistry markers of BUN, Cr, Mg, and kidney MDA are significantly different between the two sexes, and the levels of these markers were higher in males. The pathology results also confirmed greater nephrotoxicity intensity in male animals. Some other studies have confirmed the role of sex in drug-induced-nephrotoxicity (3-5, 11). Clinically, hospitalized male patients have been reported to be more vulnerable to nephrotoxicity caused by Amikacin (13). In the presence of CP, male rats excrete more sodium than female rats, which is related to cytotoxicity in kidneys (14). Previously, we presented evidence for sex-based differences in CP-induced nephrotoxicity model and in the current study; we used different doses of CP and treatment durations, which were in agreement with our pervious findings (11). L-arginine and losartan as supplementation in CP-treated animals act differently in male and female animals (9, 10). The reason for these differences is not clearly known, and at this point it seems that it is not related to female sex hormone, because estrogen itself promotes CP-induced nephrotoxicity (8, 15, 16). Gender difference in renal circulation is another probable reason for sex-related CP-induced nephrotoxicity. Simulation of angiotensin system receptors leads to different responses in the sexes (17, 18) with more vasodilator effect in female, which influences renal blood flow. The renal blood flow on the other hand is disturbed by CP (19). So, probably the female renal blood flow is reduced less by CP than male, which causes less damage. The affinity of drug binding, pharmacokinetic properties of drugs, and genetic nature are also other factors that may contribute to sex-related different responses (15, 20, 21). These factors are other proposed assumptions for this sex-based difference of lower levels of CP-induced nephrotoxicity in female. Conclusion: CP-induced nephrotoxicity is gender related due to an unknown mechanism. However, gender differences in renal circulation may be the key factor leading to this difference and this should be verified by further studies.
  18 in total

1.  Sex differences in the renal vascular response to angiotensin II involves the Mas receptor.

Authors:  T Safari; M Nematbakhsh; L M Hilliard; R G Evans; K M Denton
Journal:  Acta Physiol (Oxf)       Date:  2012-08-11       Impact factor: 6.311

2.  Gender differences in pressure-natriuresis and renal autoregulation: role of the Angiotensin type 2 receptor.

Authors:  Lucinda M Hilliard; Mehdi Nematbakhsh; Michelle M Kett; Elleesha Teichman; Amanda K Sampson; Robert E Widdop; Roger G Evans; Kate M Denton
Journal:  Hypertension       Date:  2010-12-28       Impact factor: 10.190

3.  [3H]gentamicin uptake in brush border and basolateral membrane vesicles from rat kidney cortex.

Authors:  P D Williams; G H Hottendorf
Journal:  Biochem Pharmacol       Date:  1986-07-01       Impact factor: 5.858

4.  Cisplatin increases urinary sodium excretion in rats: gender-related differences.

Authors:  Donatas Stakisaitis; Giedre Dudeniene; Rimas Jonas Jankūnas; Grazina Grazeliene; Janina Didziapetriene; Birute Pundziene
Journal:  Medicina (Kaunas)       Date:  2010       Impact factor: 2.430

5.  The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences.

Authors:  Maryam Haghighi; Mehdi Nematbakhsh; Ardeshir Talebi; Hamid Nasri; Farzaneh Ashrafi; Kambiz Roshanaei; Fatemeh Eshraghi-Jazi; Zahra Pezeshki; Tahereh Safari
Journal:  Ren Fail       Date:  2012-07-11       Impact factor: 2.606

6.  Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat.

Authors:  J A Winston; R Safirstein
Journal:  Am J Physiol       Date:  1985-10

7.  Sex-related differences in the susceptibility of rats to gentamicin nephrotoxicity.

Authors:  W M Bennett; R A Parker; W C Elliott; D N Gilbert; D C Houghton
Journal:  J Infect Dis       Date:  1982-03       Impact factor: 5.226

8.  Effect of sex hormones on gentamicin-induced nephrotoxicity in rats.

Authors:  J C Carraro-Eduardo; A V Oliveira; M E Carrapatoso; J F Ornellas
Journal:  Braz J Med Biol Res       Date:  1993-06       Impact factor: 2.590

9.  Sex difference in ischemic acute renal failure in rats: approach by proteomic analysis.

Authors:  Junji Takayama; Masanori Takaoka; Yohko Sugino; Yuji Yamamoto; Mamoru Ohkita; Yasuo Matsumura
Journal:  Biol Pharm Bull       Date:  2007-10       Impact factor: 2.233

10.  The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model.

Authors:  Fatemeh Eshraghi-Jazi; Mehdi Nematbakhsh; Hamid Nasri; Ardeshir Talebi; Maryam Haghighi; Zahra Pezeshki; Tahereh Safari; Farzaneh Ashrafi
Journal:  J Res Med Sci       Date:  2011-11       Impact factor: 1.852

View more
  36 in total

1.  Cisplatin nephrotoxicity as a model of chronic kidney disease.

Authors:  Mingjun Shi; Kathryn L McMillan; Junxia Wu; Nancy Gillings; Brianna Flores; Orson W Moe; Ming Chang Hu
Journal:  Lab Invest       Date:  2018-06-01       Impact factor: 5.662

Review 2.  Drug-induced anaemia: a decade review of reporting to the Italian Pharmacovigilance data-base.

Authors:  Carla Carnovale; Tatiana Brusadelli; Maria Luisa Casini; Francesca Renda; Sara Ruggieri; Giuseppe Pimpinella; Sonia Radice; Emilio Clementi
Journal:  Int J Clin Pharm       Date:  2014-12-17

3.  Unique sex- and age-dependent effects in protective pathways in acute kidney injury.

Authors:  Ravindra Boddu; Chunlan Fan; Sunil Rangarajan; Bhuvana Sunil; Subhashini Bolisetty; Lisa M Curtis
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-05

4.  Protective effects of amifostine, curcumin, and melatonin against cisplatin-induced acute kidney injury.

Authors:  Filiz Mercantepe; Tolga Mercantepe; Atilla Topcu; Adnan Yılmaz; Levent Tumkaya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-02       Impact factor: 3.000

Review 5.  Role of SLC transporters in toxicity induced by anticancer drugs.

Authors:  Kevin M Huang; Muhammad Erfan Uddin; Duncan DiGiacomo; Maryam B Lustberg; Shuiying Hu; Alex Sparreboom
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-04-26       Impact factor: 4.481

6.  Sex- and Gender-Based Pharmacological Response to Drugs.

Authors:  Franck Mauvais-Jarvis; Heiner K Berthold; Ilaria Campesi; Juan-Jesus Carrero; Santosh Dakal; Flavia Franconi; Ioanna Gouni-Berthold; Mark L Heiman; Alexandra Kautzky-Willer; Sabra L Klein; Anne Murphy; Vera Regitz-Zagrosek; Karen Reue; Joshua B Rubin
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

7.  Role of endothelin-1 antagonist; bosentan, against cisplatin-induced nephrotoxicity in male and female rats.

Authors:  Zahra Jokar; Mehdi Nematbakhsh; Maryam Moeini; Ardeshir Talebi
Journal:  Adv Biomed Res       Date:  2015-05-11

Review 8.  Cisplatin chemotherapy and renal function.

Authors:  Jie Zhang; Zhi-Wei Ye; Kenneth D Tew; Danyelle M Townsend
Journal:  Adv Cancer Res       Date:  2021-04-28       Impact factor: 6.242

9.  Nonpreventive Role of Aerobic Exercise Against Cisplatin-induced Nephrotoxicity in Female Rats.

Authors:  Jalaledin Noroozi; Farzaneh Zeynali; Mehdi Nematbakhsh; Zahra Pezeshki; Ardeshir Talebi
Journal:  Int J Prev Med       Date:  2015-07-08

10.  The effect of an specific inducible NO synthase inhibitor, S-methylisothiourea hemisulfate on cisplatin-induced nephrotoxicity; gender-related differences.

Authors:  Mansooreh Ghayyoomi; Nepton Soltani; Mehdi Nematbakhsh; Fatemeh Moslemi; Ardeshir Talebi; Soheila Shirdavani; Farzaneh Razmjoo
Journal:  Adv Biomed Res       Date:  2015-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.